Abstract
A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.
Translated title of the contribution | General profile of fluvoxamine |
---|---|
Original language | Italian |
Pages (from-to) | 626-650 |
Number of pages | 25 |
Journal | Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali |
Volume | 115 |
Issue number | 4 |
Publication status | Published - 1991 |
ASJC Scopus subject areas
- Psychiatry and Mental health